Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals – June 2020

GlobalData's “Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals – June 2020” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in June 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharma Intelligence Center deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, June 2020 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, June 2020 12

2.2.1 Upjohn Raises USD11.5 Billion in Private Placement of 4% Notes Due 2050 12

2.2.2 Takeda Pharma Prices Public Offering of Notes for USD7 Billion 12

2.2.3 Merck Raises USD4.5 Billion in Public Offering of Notes 12

2.2.4 Genmab and AbbVie Enter into a Co-Development Agreement 13

2.2.5 Pharma Company Enters into Licensing Agreement with Alteogen 14

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, June 2020 15

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, June 2020 16

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 17

3.1 Pharmaceuticals & Healthcare, Global, M&A, June 2020 17

3.1.1 Top M&A Deals in June 2020 18

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, January 2020– June 2020 19

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, June 2020 20

3.2.1 Top Equity Offering Deals in June 2020 21

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, January 2020– June 2020 22

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, June 2020 23

3.3.1 Top PE/VC Deals in June 2020 24

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, June 2020 25

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, June 2020 26

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, January 2020–June 2020 27

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, January 2020–June 2020 28

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, June 2020 29

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, January 2020– June 2020 30

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), June 2020 32

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, June 2020 33

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), January 2020– June 2020 34

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, January 2020– June 2020 36

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), January 2020– June 2020 37

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), January 2020– June 2020 38

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, June 2020 40

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, June 2020 40

4.2 harmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2020 41

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), January 2020– June 2020 42

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), January 2020– June 2020 43

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), January 2020– June 2020 45

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), January 2020– June 2020 47

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, June 2020 48

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, June 2020 49

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, June 2020 49

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 50

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, June 2020 50

5.1.1 Oncology – Deals of the Month 51

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, June 2020 53

5.2.1 Central Nervous System – Deals of the Month 54

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, June 2020 56

5.3.1 Infectious Diseases – Deals of the Month 58

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, June 2020 59

5.4.1 Cardiovascular – Deals of the Month 60

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, June 2020 63

5.5.1 Immunology – Deal of the Month 65

5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, June 2020 66

5.6.1 Metabolic– Deals of the Month 67

5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, June 2020 69

5.7.1 Gastrointestinal – Deals of the Month 70

6 Deal Summary by Geography 72

6.1 Pharmaceuticals & Healthcare, North America Deals, June 2020 72

6.1.1 North America – Deals of the Month 73

6.2 Pharmaceuticals & Healthcare, Europe, Deals, June 2020 75

6.2.1 Europe – Deals of the Month 76

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, June 2020 79

6.3.1 Asia-Pacific – Deals of the Month 80

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, June 2020 81

6.4.1 Rest of the World – Deals of the Month 82

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 84

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, January 2020– June 2020 84

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, January 2020– June 2020 85

8 Further Information 86

8.1 Methodology 86

8.2 About GlobalData 87

8.3 Contact Us 87

8.4 Disclosure information 87

8.5 Disclaimer 88

List of Tables

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, June 2020 12

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), June 2020 16

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 18

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, June 2020 18

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, January 2020– June 2020 19

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 21

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, June 2020 21

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 22

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 24

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, June 2020 24

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, January 2020– June 2020 25

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), June 2020 27

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), January 2020– June 2020 28

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, January 2020– June 2020 28

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), January 2020– June 2020 29

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), January 2020– June 2020 31

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2020– June 2020 32

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), June 2020 33

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), January 2020– June 2020 35

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, January 2020– June 2020 37

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), January 2020– June 2020 39

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 40

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), January 2020– June 2020 41

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), January 2020– June 2020 42

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), June 2020 44

Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, January 2020– June 2020 46

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), June 2020 48

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, June 2020 48

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, June 2020 49

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, June 2020 49

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 51

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 54

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 57

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 60

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 64

Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 67

Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 70

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 73

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 76

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 80

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 82

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), January 2020– June 2020 84

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), January 2020– June 2020 85

List of Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), January 2020– June 2020 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), June 2020 15

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), June 2020 16

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), January 2020– June 2020 17

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, January 2020– June 2020 19

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), January 2020– June 2020 20

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), January 2020– June 2020 22

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), January 2020– June 2020 23

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, January 2020– June 2020 25

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), June 2020 26

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), June 2020 26

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), January 2020– June 2020 27

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), January 2020– June 2020 29

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), January 2020– June 2020 30

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2020– June 2020 32

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), January 2020– June 2020 34

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, January 2020– June 2020 36

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, January 2020– June 2020 37

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), January 2020– June 2020 38

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), January 2020– June 2020 40

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2020– June 2020 41

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), January 2020– June 2020 42

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), January 2020– June 2020 43

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, January 2020– June 2020 45

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), January 2020– June 2020 46

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), June 2020 47

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), January 2020– June 2020 50

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), January 2020– June 2020 53

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), January 2020– June 2020 56

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), January 2020– June 2020 59

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), January 2020– June 2020 63

Figure 32: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 66

Figure 33: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), January 2020– June 2020 69

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), January 2020– June 2020 72

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), January 2020– June 2020 75

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), January 2020– June 2020 79

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), January 2020– June 2020 81

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), January 2020– June 2020 84

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), January 2020– June 2020 85

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports